SD Clinical Issues in Severe Asthma

This activity is provided by Integritas Communications.

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

A medical education communications company (MECC)-Organized Symposium at the American Thoracic Society (ATS) 2018 International Conference.

All ATS 2018 International Conference attendees are invited to attend this non-CME educational program sponsored by Integritas Communications and supported by a grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Dinner will be provided.

Target Audience

The educational design of this activity addresses the needs of allergists/clinical immunologists, pulmonologists, and other clinicians involved in the management of patients with severe asthma.

Statement of Need/Program Overview

An outsized proportion of asthma-related morbidity and mortality is borne by the 5% to 15% of affected patients who have severe forms of the disease.^1,2 These patients suffer from poorly controlled symptoms and frequent exacerbations, often despite daily treatment with high-dose inhaled corticosteroids and other long-acting controller medications.^1,2 Ongoing research has elucidated key pathophysiologic processes and other clinical parameters related to asthma severity and persistence.^2,3 In many cases, the patient’s medical history, clinical presentation, and results from biomarker testing can help classify severe asthma phenotypically.^2,3 Increasingly, this can allow physicians to personalize maintenance regimens using targeted therapies that reflect identified endotypes—ie, asthma phenotypes linked to specific underlying disease mechanisms and proinflammatory signaling cascades.^2,4,5 Several biologic medications are now available to treat certain cohorts with severe asthma, and a number of other targeted agents are in late-stage development.^5-7 Pulmonologists and other asthma specialists who manage patients with severe asthma need to stay current on the latest published trial data for newer targeted therapies, approvals from the US Food and Drug Administration, and actionable best-practice recommendations on evaluating and treating patients with severe asthma. During this Clinical Issues™ program, a panel of expert faculty will discuss and debate a series of topics related to comprehensively evaluating and longitudinally managing patients with severe asthma, including how the evolving evidence base should shape clinical decision-making and implications of new study data presented at the 2018 American Thoracic Society International Conference.

References

1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
2. Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
3. Whiteley J, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1-7 [Epub ahead of print].
4. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
5. Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
6. Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
7. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
8. Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

• Discuss severe asthma heterogeneity and disease biomarkers with a focus on Th2 cell–mediated pathophysiologic mechanisms
• Evaluate patients with severe asthma for symptom severity, exacerbation history, comorbidities, disease phenotypes, and prior treatment responses
• Differentiate the clinical profiles of current and emerging biologic medications for patients with severe asthma
• Individualize therapeutic regimens for patients with severe asthma based on disease phenotypes, ongoing assessment of symptoms, exacerbation risks, and comorbid condition

Program Agenda

6:30 - 7:00 PM   Registration and Introductions
7:00 - 7:15 PM   Severe Asthma: Pathophysiology, Heterogeneity, and Burdens
7:15 - 7:45 PM   Patient Evaluations: Biomarkers, Phenotypes, and Comorbidities
7:45 - 8:15 PM   Targeted Biologic Therapies for Severe Asthma
8:15 - 8:45 PM   Personalizing Asthma Management: Case Studies and Patient Perspectives
8:45 - 9:00 PM   Question and Answer Session

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc).
Please contact Nora Eldasher prior to the live event at neldasher@integritasgrp.com.

Fee Information

There is no registration fee for attending this program; however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.